NIM
DAWN

NEOS Investment Management’s Day One Biopharmaceuticals DAWN Stock Holding History

NEOS Investment Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,542
Closed -$138K – 655
2025
Q3 		$138K Sell
19,542
-104,768
-84% -$721K ﹤0.01% 627
2025
Q2 		$808K Buy
124,310
+33,187
+36% +$228K 0.01% 491
2025
Q1 		$723K Buy
91,123
+5,362
+6% +$57.8K 0.01% 478
2024
Q4 		$1.09M Buy
85,761
+6,878
+9% +$95.7K 0.03% 396
2024
Q3 		$1.1M Buy
78,883
+14,030
+22% +$200K 0.03% 354
2024
Q2 		$894K Buy
64,853
+20,430
+46% +$299K 0.04% 348
2024
Q1 		$734K Buy
44,423
+28,916
+186% +$433K 0.05% 317
2023
Q4 		$226K Buy
+15,507
New +$188K 0.02% 469

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NEOS Investment Management's DAWN Position: Q4 2025 in Review

NEOS Investment Management sold out of Day One Biopharmaceuticals (DAWN) in Q4 2025, closing a stake of 19,542 shares — an estimated $138K sold.

NEOS Investment Management first reported a position in DAWN in Q4 2023 and held it in 8 quarters. The position peaked at $1.1M in Q3 2024. 183 funds tracked by Wall St. Rank hold DAWN as of Q4 2025.

  • NEOS Investment Management reported no remaining Day One Biopharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • NEOS Investment Management sold 19,542 Day One Biopharmaceuticals shares in Q4 2025, an estimated $138K.
  • NEOS Investment Management first reported a position in Day One Biopharmaceuticals in Q4 2023 and held it in 8 quarters.
  • NEOS Investment Management's Day One Biopharmaceuticals position peaked at $1.1M in Q3 2024.
  • 183 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2025.

Based on NEOS Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.